Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB 722 CL Safety, PK, and PD in Healthy Volunteers
NCT02268604Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2010
- Primary completion
- Oct 2010
01
Overview
Phase 1, randomised, double-blind trial in myocardial infarction (MI) and ischemia-reperfusion injury (IRI) comparing BIIB 722 CL with Placebo (2 arms). Primary endpoints: Area under the concentration-time curve at 7 days, Maximum measured concentration at 7 days and 9 more. Started Oct 2010; status: terminated.
02
Drugs
eniporide
03
Conditions
myocardial infarction (MI)ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02268604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02268604.